Renin-Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Meta-Analysis
|
|
- Elinor West
- 6 years ago
- Views:
Transcription
1 ORIGINAL PAPER Renin-Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Meta-Analysis Mohan Palla, MD; 1 Tomo Ando, MD; 1 Emmanuel Androulakis, MD; 2 Tesfaye Telila, MD; 1 Alexandros Briasoulis, MD, PhD 1 From the Division of the Cardiology, Wayne State University School of Medicine, Detroit, MI; 1 and John Radcliffe Hospital, University of Oxford, Oxford, UK 2 The purpose of this study was to assess the effects of reninangiotensin system (RAS) inhibitors vs other antihypertensive agents on cardiovascular outcomes in hypertensive black patients. The authors performed a systematic review and meta-analysis of studies that compared the effects of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) with calcium channel blockers (CCBs), diuretics, and b-blockers in hypertensive black patients on cardiovascular outcomes. A total of 38,983 patients with a mean age of 60 years and mean follow-up of 4 years were included in our meta-analysis. No significant differences were found in all-cause mortality, myocardial infarction, heart failure, and cardiovascular mortality rates among patients treated with RAS inhibitors compared with CCBs, diuretics, and b-blockers. The incidence of stroke was significantly increased in patients treated with RAS inhibitors compared with CCBs (odds ratio, 1.56; 95% confidence interval, [P<.00001]; I 2 =0%) and diuretics (odds ratio, 1.59; 95% confidence interval, [P=.004]; I 2 =56%) but not b-blockers. J Clin Hypertens (Greenwich). 2017;19: ª 2016 Wiley Periodicals, Inc. Hypertension (HTN) in African Americans is often more severe and resistant to antihypertensive therapy and leads to earlier target organ damage and higher cardiovascular (CV) events compared with whites. 1 3 Response to antihypertensive drug classes may be different among different age and race subgroups. Black and elderly patients exhibit better blood pressure (BP) response to thiazide diuretics or long-acting calcium channel blockers (CCBs), provided they don t have a specific indication for angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) such as heart failure (HF) or proteinuric chronic kidney disease. 4 In contrast, younger white patients respond better to ACE inhibitors or ARBs. 4 6 The observed differences may be the result of lower plasma renin activity in hypertensive blacks. 7 A recent analysis of New York City Health and Hospital Corporation s clinical data showed significantly higher all-cause mortality and myocardial infarction (MI) rates in hypertensive blacks treated with ACE inhibitors. 8 We sought to review and analyze CV outcomes in hypertensive blacks treated with different antihypertensive classes. METHODS Search Strategy Systematic electronic search was performed on MED- LINE (PubMed interface), Embase, and Cochrane Address for correspondence: Alexandros Briasoulis, MD, Department of Cardiology, Detroit Medical Center, Wayne State University, Detroit, MI alexbriasoulis@gmail.com Manuscript received: March 23, 2016; revised: May 9, 2016; accepted: May 20, 2016 DOI: /jch Central Registry of Controlled Trials (CENTRAL) with no language limitations. Using the MESH terms, we searched the following key terms: hypertension, blacks, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, and b-blockers. Two reviewers (M.P. and A.B.) independently screened titles and abstracts based on inclusion and exclusion criteria. After eliminating irrelevant studies, full-text reports were reviewed. Review articles were excluded. Subsequently, we performed a hand search of all included randomized clinical trials and observational studies until no further relevant studies were identified. Finally, a total of four studies were identified. Study Selection We included randomized clinical trials and observational studies published as original articles in peerreviewed scientific journals. We studied hypertensive blacks who were treated with ACE inhibitors or ARBs compared with CCBs, diuretics, and b-blockers. We excluded studies that were performed in nonblacks. Outcomes Assessed The primary outcomes measured were all-cause mortality, MI, stroke, HF, and CV mortality. The secondary outcome measured was the composite outcome of allcause mortality, MI, stroke and HF. Data Extraction and Quality The data were independently extracted by two authors (M.P. and A.B.) using standardized protocol and reporting form. We extracted outcome measures data; study characteristics such as trial design, year of study, sample size, inclusion criteria and exclusion criteria, primary and secondary outcomes, and follow-up duration; and baseline patient characteristics. 344 The Journal of Clinical Hypertension Vol 19 No 4 April 2017
2 Risk of Bias Cochrane s risk of bias tool was used to assess the individual risk of bias of each study. The Newcastle- Ottawa tool was used for the quality assessment of cohort studies. Low-quality studies had two or more quality assessment criteria qualified as high or unclear risk of bias. The small study effect, including publication bias, was tested using funnel plot and the Egger s test. Data Analysis, Summary Measures, and Synthesis of Results Systematic review and meta-analysis was performed in compliance with the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. Meta-analysis was performed by using Review Manager (RevMan) Version 5.2 (Nordic Cochrane Centre, The Cochrane Collaboration, 2012, Copenhagen, Denmark). Chi-square test of heterogeneity and I 2 statistic of inconsistency were used to assess the heterogeneity between studies. I 2 values of 25%, 50%, and 75% were considered as low, moderate, and high heterogeneity, respectively. 9 Significant heterogeneity was considered if the P<.05 or an I 2 statistic >25%. Pooled effect of intervention was measured using odds ratios (ORs) with 95% confidence intervals (CIs). DerSimonian and Laird s random-effects model was used. Reported values are two-tailed, and hypothesis-testing results were considered statistically significant at P<.05. Significant heterogeneity between the studies was further explored using subgroup analyses. RESULTS Study Selection After electronic search of scientific literature with omission of duplicate trials and screening of titles followed by review of abstracts and full texts, four studies were identified and included in the meta-analysis based on inclusion and exclusion criteria Of the four studies, three were subgroup analyses of randomized control trials 9 11 and one was a propensitymatched cohort analysis. 8 ACE inhibitors were compared with CCBs in the African American Study of Kidney Disease and Hypertension (AASK) trial, 11 the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial, 10 and Bangalore and colleagues 8 ; diuretics in the ALLHAT trial 10 and Bangalore and colleagues 8 ; and b-blockers in the AASK trial, 11 Bangalore and colleagues, and the Losartan Intervention For Endpoint Reduction (LIFE) study. 9 All included studies were deemed to be at low risk of bias. Study Characteristics A total of 38,983 patients with a mean age of 60 years and mean follow-up of 4 years were included in our meta-analysis. The characteristics of each study are shown in the Table. Baseline BP and BP reduction were TABLE. Interventions and Characteristics of Individual Studies Mean Baseline BP, mm Hg Mean Change of BP, mm Hg ACE ACE Inhibitor CCB Diuretic BB Inhibitor CCB Diuretic BB Mean Follow-Up, y Antihypertensive Agent Sample Size Mean Follow-Up Period Mean Study Study Design Age, y Randomized y Losartan/atenolol 270/ / / / / 17.2 clinical trial 66 4 y Lisinopril/amlodipine/ 3210/5369/ / / / / / / 6.6 chlorthalidone y Ramipril/amlodipine/ 436/217/ /96 150/96 150/95 16/ 14 17/ 15 15/ 14 metoprolol 50 6 mo ACE/CCB/diuretic/BB Total sample 6 144/83 153/87 148/85 138/80 25,564 Randomized clinical trial Randomized clinical trial Propensity match cohort LIFE Study (2004) ALLHAT study (2005) AASK trial (2006) Bangalore et al. (2015) Abbreviations: AASK, African American Study of Kidney Disease and Hypertension trial; ACE, angiotensin-converting enzyme; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; BB, b-blocker; BP, blood pressure; CCB, calcium channel blocker; LIFE, Losartan Intervention For Endpoint Reduction trial. The Journal of Clinical Hypertension Vol 19 No 4 April
3 FIGURE 1. Random-effect meta-analysis of the effects of renin-angiotensin system (RAS) inhibitors vs calcium channel blockers (CCBs) on allcause mortality, myocardial infarction, stroke, heart failure, and composite outcome. The figure presents number of events, number of patients in the treatment and control groups, odds ratio (OR) and 95% confidence interval (CI) for each trial, overall OR estimate with 95% CI and P value for association test, P value for heterogeneity test, and between-trial inconsistency (I 2 ) measures. ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. not available in all studies. Because of variability in study design, baseline BP, and BP reduction among studies, we did not perform a separate meta-analysis of these BP variables. RAS Inhibitors vs CCBs No significant differences were found in all-cause mortality (Figure 1a), MI (Figure 1b), HF (Figure 1d), and CV mortality rates when ACE inhibitors were compared with CCBs. However, the incidence of stroke was significantly increased in patients treated with ACE inhibitors (OR, 1.56; 95% CI, [P<.00001]; I 2 =0%) without significant heterogeneity among studies (Figure 1c). There was a trend towards significantly increased composite outcome with ACE inhibitors (OR, 1.27; 95% CI, [P=.05]; I 2 =79%) with significant heterogeneity among studies (Figure 1e). After the exclusion of the cohort study by Bangalore and colleagues, the association between treatment of ACE inhibitors and composite CV outcome became significant (OR, 1.14;95% CI, [P=.01]; I 2 =0%). RAS Inhibitors vs Diuretics We did not detect any significant difference in all-cause mortality (Figure 2a), MI (Figure 2b), HF (Figure 2d), and CV mortality rates when ACE inhibitors were compared with thiazide diuretics. The stroke rates were significantly higher in patients treated with ACE inhibitors (OR, 1.59; 95% CI, [P=.004]; I 2 =56%) (Figure 2c) without significant heterogeneity 346 The Journal of Clinical Hypertension Vol 19 No 4 April 2017
4 FIGURE 2. Random-effect meta-analysis of the effects of renin-angiotensin system (RAS) inhibitors vs diuretics on all-cause mortality, myocardial infarction, stroke, heart failure, and composite outcome. The figure presents number of events, number of patients in the treatment and control groups, odds ratio (OR) and 95% confidence interval (CI) for each trial, overall OR estimate with 95% CI and P value for association test, P value for heterogeneity test, and between-trial inconsistency (I 2 ) measures. ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. among studies. A trend towards increased composite CV outcomes was observed (P=.05) (Figure 2e). RAS Inhibitors vs b-blockers No significant differences were found in all-cause mortality (Figure 3a), MI (Figure 3b), stroke (Figure 3c), HF (Figure 3d), and CV mortality when RAS inhibitors were compared with b-blockers. However, there was a significantly increased composite outcome with RAS inhibitors (OR, 1.20; 95% CI, [P=.02]; I 2 =81%) with significant heterogeneity among studies (Figure 3e). As certain side effects such as cough and angioedema are more frequent with ACE inhibitors than ARBs and may lead to differences in medication adherence, we performed subgroup analysis of studies with ACE inhibitors only with exclusion of the LIFE study. No significant differences in all-cause mortality, MI, stroke, HF, CV mortality, and composite outcome were found between groups. The funnel plot did not show asymmetry consistent with publication bias, and the Egger s test was not significant for the outcomes studied. DISCUSSION Our meta-analysis compared the effects of RAS inhibitors with other main classes of antihypertensive agents in hypertensive blacks and showed no significant difference in all-cause mortality, MI, HF, and CV death among patients treated with RAS inhibitors, CCBs, diuretics, and b-blockers. The incidence of stroke was higher in patients treated with ACE inhibitors compared with CCBs and diuretics. The Journal of Clinical Hypertension Vol 19 No 4 April
5 FIGURE 3. Random-effect meta-analysis of the effects of renin-angiotensin system (RAS) inhibitors vs b-blockers on all-cause mortality, myocardial infarction, stroke, heart failure, and composite outcome. The figure presents number of events, number of patients in the treatment and control groups, odds ratio (OR) and 95% confidence interval (CI) for each trial, overall OR estimate with 95% CI and P value for association test, P value for heterogeneity test, and between-trial inconsistency (I 2 ) measures. ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Hypertensive blacks are considered to have suppressed plasma renin activity and dietary salt-induced suppression of renin production and fit the Laragh and Sealey model of volume-expanded hypertension. 12 However, prior studies have not confirmed this perception as they showed higher RAS activation and blunted suppression of intrarenal RAS activity compared with whites after high sodium intake Hypertensive blacks are more likely to be obese; have higher apneahypopnea index, dietary salt intake, and salt sensitivity; and lower dietary intake of potassium and socioeconomic status compared with hypertensive whites. 15 These confounding factors may explain differential interracial response to specific antihypertensive classes. Although high sodium intake is associated with less BP response to ACE inhibitors among all races, blacks with higher sodium intake exhibit consistently less BP reduction when treated with ACE inhibitors. 16 However, the intraracial variability of BP response to monotherapy with RAS inhibitors is greater that the interracial variability. 17 Based on the above we can conclude that race differences in BP response to RAS inhibitors are the result of differences in individual baseline characteristics rather than a single pathophysiologic mechanism. A previous meta-analysis of 13 clinical trials showed that ACE inhibitor monotherapy was associated with 4.6/2.8 mm Hg less BP reduction compared with other antihypertensives, with ACE inhibitor dose being the only factor mitigating the BP difference. 18 These 348 The Journal of Clinical Hypertension Vol 19 No 4 April 2017
6 differences in BP response were similar to those reported by the ALLHAT trial. 10 The BP data provided by individual studies were not sufficient for accurate metaanalysis of BP reduction. Furthermore, the medication regimens and doses differ in each study. Therefore, the heterogeneity among studies would be a limiting factor for meta-analysis of BP reduction. However, the currently available data suggest that the differences in stroke rates were driven mainly by the ALLHAT trial and the study by Bangalore and colleagues. Although the analysis by Bangalore and colleagues did not provide BP data, the ALLHAT trial showed poorer BP control with lisinopril compared with amlodipine and chlorthalidone. Therefore, the most likely explanation for the differences in stroke rates is less BP reduction with ACE inhibitor/arbs monotherapy. Both ACE inhibitors and ARBs seem to have antiinflammatory effects. A prospective controlled doubleblind study of hypertensive patients suggested that treatment with olmesartan significantly reduced a panel of inflammation markers (high-sensitivity C-reactive protein, tumor necrosis factor a, and interleukin 6) compared with controls. 19 In a smaller randomized controlled trial of 21 hypercholesterolemic volunteers, both enalapril and losartan induced a small but stable decrease in levels of adhesion molecules. 20 However, these mild anti-inflammatory effects observed in a small number of patients may not have meaningful impact on stroke rates and CV outcomes if not accompanied by significant BP reduction. 21 One of the main reasons RAS antagonists may be less effective antihypertensive agents in African Americans is the different dose response compared with whites. 22 African Americans require higher doses of ACE inhibitors to achieve equivalent reductions in BP with whites. 23 Furthermore, since hypertensive blacks are likely to require more than a single antihypertensive, the use of combination therapy including an ACE inhibitor or ARB effectively decreases BP and CV events 24 and the combination with a diuretic may eliminate race-specific differences in dose response. 23 In addition, as the AASK trial results demonstrated, hypertensive blacks with target organ damage such as chronic kidney disease or HF may benefit from ACE inhibitors more than other hypertensive classes in spite of lesser BP reduction. 11 Although we did not observe significant differences in HF between ACE inhibitors/arbs and CCBs, the use of the latter as monotherapy should be discouraged in patients with reduced left ventricular function. It is unclear whether ACE inhibitors and ARBs have similar effects on BP reduction in hypertensive blacks. The LIFE study showed that hypertensive blacks did not respond as favorably to losartan-based treatment as nonblack patients with respect to CV outcomes despite greater electrocardiographic left ventricular hypertrophy reduction with losartan compared with atenolol. 11 In our study, the sensitivity analysis of studies with ACE inhibitors after exclusion of the LIFE study, showed similar outcomes with ACE inhibitors and b-blockers. STUDY LIMITATIONS There are some limitations to the interpretation of our data analysis. First, publication bias may still exist despite our best efforts to conduct a comprehensive search and the lack of statistical evidence for the existence of bias. Second, any meta-analysis based on pooling of data from different trials with different inclusion criteria, different designs and populations, and variable follow-up duration with differing attrition rates presents challenges. The antihypertensive regimens and dosages used in individual studies were also different and may have differential effects on outcomes. Third, the ability of the analyses to detect differences between regimens would have been diminished by incomplete adherence to assigned treatments and the extensive use of add-on therapies. Fourth, outcomes evaluated here were not available as prespecified criteria or primary outcomes in all eligible trials. Fifth, we included mainly US-based trials, thus our results may not be applicable to other black populations such as African blacks, representing different patterns of CV risk. Lastly, absence of analysis on BP reduction limits the interpretation of the differences in stroke rates. CONCLUSIONS This is a hypothesis-generating analysis demonstrating similar effects of RAS inhibitors on all-cause mortality, MI, HF, and CV mortality compared with CCBs and diuretics but higher stroke rates. The difference in stroke may be the result of lesser BP reduction with RAS inhibition as a consequence of interracial differences in sodium intake, salt sensitivity, and comorbid conditions. Therefore, future trials should specifically investigate baseline characteristics that lead to BP response variability and potentially to higher stroke rates with RAS inhibitor monotherapy. Acknowledgment and Disclosure: The authors have no acknowledgments or conflicts of interest to declare and no funding for the current work. No ethical approval was needed. References 1. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56: Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141: Jolly S, Vittinghoff E, Chattopadhyay A, Bibbins-Domingo K. Higher cardiovascular disease prevalence and mortality among younger blacks compared to whites. Am J Med. 2010;123: Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328: James PA, Oparil S, Carter BL, et al evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311: Mancia G, Fagard R, Narkiewicz K, et al ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31: The Journal of Clinical Hypertension Vol 19 No 4 April
7 7. Blaufox MD, Lee HB, Davis B, et al. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA. 1992;267: Bangalore S, Ogedegbe G, Gyamfi J, et al. Outcomes with angiotensin-converting enzyme inhibitors vs other antihypertensive agents in hypertensive blacks. Am J Med. 2015;128: Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004;43: Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293: Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006;48: Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens. 2004;17: Price DA, Fisher ND, Osei SY, et al. Renal perfusion and function in healthy African Americans. Kidney Int. 2001;59: Price DA, Fisher ND, Lansang MC, et al. Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt. Hypertension. 2002;40: Flack JM, Staffileno BA. Hypertension in blacks. In: Johnson R, ed. Comprehensive Clinical Nephrology. London, UK: Mosby International; Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensinconverting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31: Mokwe E, Ohmit SE, Nasser SA, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation Trial. Hypertension. 2004;43: Peck RN, Smart LR, Beier R, et al. Difference in blood pressure response to ACE-inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials. BMC Nephrol. 2013;14: Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110: Graninger M, Reiter R, Drucker C, et al. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol. 2004;44: Sica D. Are there pleiotropic effects of antihypertensive medications or is it all about the blood pressure in the patient with diabetes and hypertension? J Clin Hypertens (Greenwich). 2011;13: Weir MR, Saunders E; Trandolapril Multicenter Study Group. Renin status does not predict the anti-hypertensive response to angiotensinconverting enzyme inhibition in African-Americans. J Hum Hypertens 1998;12: Flack J, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin. 2000;16: Weir MR, Bakris GL, Weber MA, et al. Renal outcomes in hypertensive black patients at high cardiovascular risk. Kidney Int. 2012;81: The Journal of Clinical Hypertension Vol 19 No 4 April 2017
Hypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationRandomized Design of ALLHAT BP Trial
Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationTarget Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD
Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationChoice of therapy in esse... http://www.uptodate.co... Page 1 of 28 Official reprint from UpToDate www.uptodate.com Print Back Choice of therapy in essential hypertension: Recommendations Authors Norman
More informationThe JNC 8 Guidelines: A Clinical Review
8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationChapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University,
Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 12-30-2016 Assessment of Achieved Systolic Blood Pressure in Newly Treated Hypertensive Patients
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationRationale for the use of Single Pill Combination. Yong Jin Kim, MD Seoul National University Hospital
Rationale for the use of Single Pill Combination Yong Jin Kim, MD Seoul National University Hospital Unmet Need of Hypertension Treatment Hypertension # 1 Risk Factor for Global Mortality 0 1 2 3 4 5 6
More informationRationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC
Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Seung Woo Park, MD Samsung Medical Center BP Control Rates in Asia BP controlled BP uncontrolled 24.3% 36.6% 19% Turkey
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationFirst line treatment of primary hypertension
First line treatment of primary hypertension Dr. Vijaya Musini Assistant Professor, Dept. Anesthesiology, Pharmacology and Therapeutics Manager, Drug Assessment Working Group Therapeutics Initiative Editor,
More informationEvolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)
Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationOutcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril JAMA. 2005;293:
ORIGINAL CONTRIBUTION Outcomes in Hypertensive and Patients Treated With, Amlodipine, and Lisinopril Jackson T. Wright, Jr, MD, PhD J. Kay Dunn, PhD Jeffrey A. Cutler, MD Barry R. Davis, MD, PhD William
More informationExplore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationDiversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationExecutive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1
IQWiG Reports Commission No. A05-09 Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 Executive Summary 1 Translation of the executive summary of the final
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationABSTRACT KEYWORDS: The prevalence of hypertension varies from percentages in all
85 P a g e International Standard Serial Number (ISSN): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences 6(6): November-December 2017 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND
More informationClinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
More informationImproving Medical Statistics and Interpretation of Clinical Trials
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationTouyz, R. M., and Dominiczak, A. F. (2016) Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets? Hypertension, 67(4), pp. 688-689. There may be differences between this
More informationEFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION
EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More information2017 High Blood Pressure Clinical Practice Guideline
2017 High Blood Pressure Clinical Practice Guideline Applying the Latest Hypertension Guideline to Your Practice Carmine D Amico, D.O., F.A.C.C. 2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH /
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationAbbreviations Cardiology I
Cardiology I and Clinical Controversies Joseph J. Saseen, Pharm.D., FCCP, BCPS (AQ Cardiology) Reviewed by Stuart T. Haines, Pharm.D., FCCP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning
More informationHypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington
Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationJackson T. Wright, Jr. MD, PhD
DIFFERENTIAL EFFECTS OF BLOOD PRESSURE MEDICATIONS IN BLACK PATIENTS Jackson T. Wright, Jr. MD, PhD Professor of Medicine Program Director, WT Dahms MD Clinical Research Unit Clinical and Translational
More informationPrescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines
American Journal of Pharmacology and Toxicology Original Research Paper Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines 1 Krishna Murti, 1 M. Arif Khan, 1 Akalanka Dey,
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationPeer Review Report. [Fixed Dose Combination Lisinopril + Hydrochlothiazide]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [Fixed Dose Combination Lisinopril + Hydrochlothiazide] (1) Does the application adequately address the issue of the
More informationAmlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy
ORIGINAL ARTICLE Korean J Intern Med 2014;29:315-324 and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy Seung-Ah Lee 1,
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationTreatment of Hypertension
This Clinical Resource gives subscribers additional insight related to the Recommendations published in January 2018 ~ Resource #340101 Treatment of Hypertension In 2013, the JNC 8 panel released recommendations
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationMetabolic Consequences of Anti Hypertensives: Is It Clinically Important?
Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents
More informationWhen should blood pressure be lowered? Should treatment be guided by blood pressure values or total cardiovascular risk?
OF JOURNAL HYPERTENSION JH R RESEARCH Journal of HYPERTENSION RESEARCH www.hypertens.org/jhr Editorial J Hypertens Res (2016) 2(2):47 51 When should blood pressure be lowered? Should treatment be guided
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationManagement of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationALLHAT Investigators Report 10-Year Follow-up and Stand by Diuretics as First-Step Antihypertensive Treatment
1 sur 5 21/11/2009 07:26 www.medscape.com Medscape Medical News from the: American Heart Association (AHA) 2009 Scientific Sessions This coverage is not sanctioned by, nor a part of, the American Heart
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More information